MARKET

GBT

GBT

Global Blood
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.33
+0.49
+1.83%
After Hours: 27.33 0 0.00% 16:00 05/20 EDT
OPEN
27.23
PREV CLOSE
26.84
HIGH
27.50
LOW
26.04
VOLUME
1.21M
TURNOVER
0
52 WEEK HIGH
41.73
52 WEEK LOW
22.67
MARKET CAP
1.78B
P/E (TTM)
-5.6253
1D
5D
1M
3M
1Y
5Y
Global Blood Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42 million.
Benzinga · 2d ago
Global Blood, Impel Pharma could be M&A targets after Biohaven deal - analysts
Global Blood Therapeutics (NASDAQ:GBT) may be a potential acquisition candidate in the biotech space following Pfizer (PFE)'s deal to acquire Biohaven Pharmaceutical for about $11.6 billion, according to a Wedbush
Seekingalpha · 05/15 13:00
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today annou...
GlobeNewswire · 05/12 14:00
Shareholders in Global Blood Therapeutics (NASDAQ:GBT) have lost 58%, as stock drops 24% this past week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...
Simply Wall St. · 05/11 14:24
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2022, the compensation committee of GBT’s board of directors granted 14 new employees restricted stock units fo...
GlobeNewswire · 05/05 20:05
GBT Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in fireside chats at the following investor conferences: Bank of America Securities 2022 Healthcare C...
GlobeNewswire · 05/05 20:05
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
Zacks · 05/05 14:22
--HC Wainwright Adjusts Global Blood Therapeutics' Price Target to $65 from $75, Keeps Buy Rating
MT Newswires · 05/05 13:40
More
No Data
Learn about the latest financial forecast of GBT. Analyze the recent business situations of Global Blood through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

36.36%Strong Buy
40.91%Buy
22.73%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GBT stock price target is 59.63 with a high estimate of 102.00 and a low estimate of 31.00.
High102.00
Average59.63
Low31.00
Current 27.33
EPS
Actual
Estimate
-1.09-0.82-0.54-0.27
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 337
Institutional Holdings: 75.60M
% Owned: 116.13%
Shares Outstanding: 65.10M
TypeInstitutionsShares
Increased
74
7.43M
New
30
2.67M
Decreased
62
1.60M
Sold Out
30
3.53M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
President/Chief Executive Officer/Director
Ted Love
Chief Financial Officer
Jeffrey Farrow
Chief Human Resource Officer
Eric Fink
Chief Scientific Officer
Brian Cathers
Other
Jung Choi
Other
David Johnson
Other
Tricia Suvari
Lead Director/Independent Director
Mark Perry
Non-Executive Director
Willie Brown
Independent Director
Scott Morrison
Independent Director
Deval Patrick
Independent Director
Glenn Pierce
Independent Director
Philip Pizzo
Independent Director
Dawn Svoronos
Independent Director
Alexis Thompson
Independent Director
Wendy Yarno
No Data
No Data
About GBT
Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The company has introduced Oxbryta (voxelotor) tablets, the Food and Drug Administration (FDA) approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The Company is also focused on its pipeline program in SCD with inclacumab, which is a P-selectin inhibitor in Phase III development to address pain crises associated with the disease. The Company is also in the development of its hemoglobin polymerization inhibitor, GBT601, which is a molecule discovered and designed by scientists at the Company.

Webull offers kinds of Global Blood Therapeutics Inc stock information, including NASDAQ:GBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GBT stock methods without spending real money on the virtual paper trading platform.